Spiegel R. — Psychopharmacology: an introduction :: Электронная библиотека попечительского совета мехмата МГУ

Главная Ex Libris Книги Журналы Статьи Серии Каталог Wanted Загрузка ХудЛит Справка Поиск по индексам Поиск Форум

Авторизация

Поиск по указателям

Spiegel R. — Psychopharmacology: an introduction

Обсудите книгу на научном форуме

Нашли опечатку?
Выделите ее мышкой и нажмите Ctrl+Enter

Название: Psychopharmacology: an introduction

Автор: Spiegel R.

Аннотация:

Describes the latest advances in psychopharmacology - one of the most rapidly developing fields in modern science. This latest edition has been updated to cover new developments in drug therapy and research including newly introduced antipsychotics, antidepressants and antidementia drugs. Sections on the treatment of depression and dementia have been revised to include new developments in treatment strategies. It will be welcomed for its essentially clinical and psychological approach to modern pharmaceuticals, their therapeutic uses and limitations, adverse reactions and future directions for research.

Язык:

Рубрика: Медицина и здравоохранение/

Статус предметного указателя: Готов указатель с номерами страниц

ed2k: ed2k stats

Издание: fouth edition

Год издания: 2003

Количество страниц: 400

Добавлена в каталог: 11.12.2005

Операции: Положить на полку | Скопировать ссылку для форума | Скопировать ID

Предметный указатель

Behavior, human, executive functions      227
Behavior, human, observation of      195—196
Behavior, human, variations in      64
Behavioral and psychiatric symptoms of dementia (BPSD)      255—256
Behavioural Pathology in Alzheimer's Disease (BEHAVE-AD)      203—204
Belladonna      34—35
Benzamides, in functional imaging      208
Benzocramine      12
Benzodiazepines      44
Benzodiazepines and CFF technique      93
Benzodiazepines as anxiolytics      18 90—91 134 136
Benzodiazepines, actions of      124 188
Benzodiazepines, alternatives to      22—23 292—295
Benzodiazepines, as hypnotics      18 90—91 134 136
Benzodiazepines, binding site      106
Benzodiazepines, dependency on      21—22
Benzodiazepines, effects of      82—85 (84) 90—91 242—245
Benzodiazepines, effects of, amnestic      84
Benzodiazepines, interactions      161—162
Benzodiazepines, need for legislation on      22—23
Benzodiazepines, negative effects of      20
Benzodiazepines, performance parameters and      83 146
Benzodiazepines, structure      49
Benzodiazepines, studies/trials on      73 218
Benzodiazepines, tolerance and withdrawal symptoms      53
Benzodiazepines, uses of      18
Benzodiazepines, withdrawal symptoms of      21—22
Berger, H.      70 72
Beta-receptor blockers (beta-blockers)      18 124 292—293
Bias, minimization methodology      179—180
Bioavailability      159
Bipolar disorder      15—16 128 173 182 241 307
Bipolar disorder, acute depression, treatment during      279
Bipolar disorder, acute mania, treatment during      278—279
Bipolar disorder, maintenance treatments for      279
Bipolar disorder, patients      82
Bipolar disorder, psychoses      43
Bipolar disorder, treatment with mood stabilizers      278—279
Bipolar disorder, types of      15 see also depression
Bleuler, E.      35—36 228 319
Blood flow, cerebral, measurement of      218—221
Blood pressure, decrease in      3 8 18
Blood pressure, increase in      14
Blood-brain barrier      6 157 187 209 215—216 223
Body growth, retardation of      25
Boston — New Haven Study      280—282 (241)
Boyle, R.      221
BPRS      see Brief Psychiatric Rating Scale
BPSD      see behavioral and psychiatric symptoms of dementia
Brain, complexity of      102
Brain, disorder, organic      3
Brain, dopaminergic activity      58
Brain, imaging      162
Brain, mapping      72
Brain, metabolism, enhancers      26
Brain, metabolism, measurement of      215—218
Brain, relaxation parameters in      213
Brain, salts      35—36
Brain-behavior relationships      58
Breast enlargement, caused by anti-psychotics      7
Breathing difficulties      292
Bridging studies/trials      186
Brief Psychiatric Rating Scale (BPRS)      201—202
British Drug Houses      44
Bromazepam      19
Bromine, $(^{76}Br)$ halides, in functional imaging      209
Bromocriptine      115
Bronchitis      254
Bronchospasm      293
Bupropion      11 12 14 276
Bupropion, effects of      79—81 (80)
Buspar $\textregistered$       19
Buspirone      19 23 124 293 296 246
Buspirone, effects of      82 84—85 90
Butanol, in functional imaging      209 218
Cade, J.      27 43 47 49
Caffeine      2 59 85—87 91 95 296
Caffeine, coffee      60 87
Caffeine, improved performance by      60—61
Calgary Depression Scale for Schizophrenia (CDSS)      199
Caps      see Clinician-Administered PTSD Scale
Carbamate      256
Carbamazepine      16 160—162 241 278—279
Carbamazepine, side effects of      17
Carbon $(^{11}C, ^{14}C)$ , in functional imaging      209—210 215
Carbon dioxide inhalation challenge      187—188
Carbon monoxide, in functional imaging      209
Cardiac arrhythmias      25 293
Cardiazole shock      46
Carlsson, A.      52
cat      see computerized axial tomography
Catalepsy      114
Cataplexy      24
Catapres $\textregistered$       3
Catechol-o-methyltransferase (COMT)      126
Catechol-o-methyltransferase (COMT), inhibitor      313—314
Catecholamines      293
CBT      see cognitive-behavioral therapy
CDSS      see Calgary Depression Scale for Schizophrenia
Celexa $\textregistered$       11
Center of Epidemiologic Studies Depression Scale (CES-D)      199
Central nervous system (CNS)      100—101 112—113 124—125 158 160 162
Centrax $\textregistered$       19
CERAD      see Consortium for the Establishment of a Registry of Alzheimer's Disease
Cerebrovascular disease      253
CES-D      see Center of Epidemiologic Studies Depression Scale
CFF      see critical flicker fusion frequency
Challenge      187—188
Challenge paradigms in      187—189
Challenge tests      187—188
Children      296—297
Chloral hydrate      35—36 59
Chloral hydrate, paralysing action of      60
Chlordiazepoxide      19 45 46—18 95 135—136
Chlordiazepoxide, properties of      45
Chlorimipramine      12 284
Chloroform      34—35 59 70
Chlorpromazine      5 41 59 113 163 232
Chlorpromazine and QT interval      163
Chlorpromazine, antipsychotic effect of      47—48 112 127
Chlorpromazine, discovery/introduction of      4 36—40 43 45—46 49—50 55
Chlorpromazine, effects of      27 76—79 89 95 114 230 279
Chlorpromazine, psychopharmacology before      32—36
Chlorpromazine, studies/trials of      263 271
Chlorpromazine, use in psychiatry      42 47—48
Chlorprothixene      5 12
Cholecystokinin      110
Cholesterol      311
Cholesterol, inhibitors      258—259
Cholestyramine      311
choline      54
Cholinergic drugs (cholinergics)      55—56 88—89 255—256
Cholinergic drugs (cholinergics), benefits in AD      55
Cholinergic drugs (cholinergics), therapeutic margin of      55
Cholinergic function, enhancing of      54
Cholinergic hypothesis of Alzheimer's disease      53 255
Cholinergic receptors, stimulation of      54
Cholinesterases, inhibition of      26 54—56 88—89 91 94 96 255—256
Cholinomimetics      54
Chronic mild stress model      133
Ciatyr      5
Citalopram      11 Plate
Citalopram and depression      276
Citalopram, action spectra of      12
Citalopram, effects of      79 81
Citalopram, S-enantiomer of      11
Citalopram, serotonin specificity of      126
Citalopram, side effects of      14
Citalopram, studies/trials on      191
Citalopram, uses of      292—293

CIWA-Ar      see Clinical Institute Withdrawal Assessment for Alcohol Scale
Clark, A.J.      221
Clinical efficacy      303
Clinical endpoint      164
Clinical endpoint, intermediate      164
Clinical endpoint, primary      164
Clinical endpoint, ultimate outcome      164
Clinical global impression severity scores      193
Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)      204
Clinical research in psychopharmacology      145—205
Clinical research in psychopharmacology, ethical aspects of      148—153
Clinical trials, dose-response trials      190—191
Clinical trials, endpoints and markers in      162—164
Clinical trials, pharmacokinetic-pharmacodynamic aspects of      155—162
Clinical trials, Phase I      183—186
Clinical trials, Phase IIa      147 186—190
Clinical trials, Phase IIb      147 190—193
Clinical trials, Phase III      147 190—193
Clinical trials, Phase IV      193—194
Clinical trials, proof-of-concept      147 186—190
Clinician-Administered PTSD Scale (CAPS)      201
Clinician-Administered PTSD Scale (CAPS), versions of      201
Clobazam      19 84
Clobazam, properties of      245
Clomipramine      11
Clomipramine and GAD      293
Clomipramine and neurotransmitters      126
Clomipramine and OCD      292
Clomipramine, antidepressant effect of      53 236
Clomipramine, antipanic effect of      187
Clomipramine, studies/trials on      82
Clonazepam      19
Clonazepam and anxiety syndromes      296
Clonazepam and GAD      293—294
Clonazepam, antipanic effect of      188
Clonidine      3
Clopenthixol      5 6
Clorazepate      19
Clorgyline      226
Clozapine      5
Clozapine and bipolar disorder      279
Clozapine, discovery/introduction of      46 50—52 55 114 127
Clozapine, effects of      77—79 89 95 131 234 264
Clozapine, effects of, hypothesis for      116—117
Clozapine, side effects of      7
Clozapine, studies/trials of      155 177 181 230—233
Clozapine, uses of      16
Clozaril $\textregistered$       5
Clyde Mood Scale      64
Cmmahis sativa      28
CNV      see contingent negative variation
co-dergocrine mesylate      26 87 89
Cocaine      1—2 10 115
Cocaine, brain metabolism and      217—218
Codeine      35
Coffee      see caffeine
Cognex $\textregistered$       26 54
Cognitive decline, cholinergic dysfunction and      53
Cognitive deficits      26
Cognitive function, and psychotropic drugs      227—259
Cognitive therapy and drug treatment      284
Cognitive therapy, studies in depression      283—286
Cognitive-behavioral therapy (CBT)      283 285 292 295
Cola drink      87
Coma, insulin-induced      36
Comorbidity      155 194 249
Comorbidity, anxiety /depression      125
Comorbidity, psychiatric      128 194
Compliance      266—267 305—306
Complications      13
Compulsion      40
Computer assisted tomography      254
Computerized axial tomography (CAT)      211
Comtan $\textregistered$       313
Comtan, five-year result model for      314
Concentration and attention      58 65 185
Concentration and attention, controlled studies      193
Concentration and attention, tests of      66
Concept formation and reasoning      69—70
Concerta $\textregistered$       25
Confusion      235
Consortium for the Establishment of a Registry of Alzheimer's Disease (CERAD)      255
Constipation      8 13—14 18 240
Contingent negative variation (CNV)      76
Continuation therapy, of depressive episodes      277
Contract research organizations (CROs)      58—59
Controlled trials      11
Corpus Hippocraticum      28 110
Corticosteroids      242
Corticotrophin-releasing-factor (CRF)      141—142
Corticotrophin-releasing-factor (CRF) and anxiety and depression      122
Corticotrophin-releasing-factor (CRF), receptor antagonists      122
Cortisol      242
Cost-benefit analysis      308 312—313 317
Cost-effectiveness analysis      308—309
Cost-effectiveness ratio      308—309
Cost-minimization analysis      308 312 317
Cost-utility analysis      308 309—312
Costs of informal caregiving      304—305
Costs, direct      304
Costs, indirect      305
Covi Anxiety Scale      198 200
Cracow, University of      44
CRF      see corticotrophin-releasing-factor
Critical flicker fusion frequency (CFF)      66—67 77 80—81 84 86 93
CROs      see contract research organizations
Crossover designs      178—179
Curare      38
Cushing's syndrome      242
Cvcloserine      117
Cyclic adenosine monophosphate (cAMP)      104
Cyclic guanosine monophosphate (cGMP)      104
Cylert $\textregistered$       25
CYP enzymes      160—161
d-amphetamine      25 86—87 88 92 95—96
D-serine      117
Dalmane $\textregistered$       19
Dapotum $\textregistered$       5
DATUM      35
Datum, stramonium      34
Davidson Trauma Scale (DTS)      201
Declaration of Helsinki      149 325—330 Paragraph
Declaration of Helsinki, clarification of      329—330
Degradation      106
Delay, J.      39 47
Delirium      13 235
Delirium, tremens      179
Delusions      3 6 34 228—229
Delusions in Alzheimer's disease      256
Delusions in schizophrenia      41 151 232
Delusions, psychotic      4
Delusions, risk of      24
Dementia      253
Dementia of Alzheimer type      26
Dementia Rating Scale (DRS)      254
Dementia, cognitive changes of      252—253
Dementia, praecox      228
Dementia, scales for      203—204
Dementia, underlying causes of      253
Deniker, P.      39 49
Deoxyhemoglobin      213—214
Depakene $\textregistered$       16
Depakote $\textregistered$       16
Department of Education, USA      250
Dependency      261
Depot antipsychotics      267
Deprenyl      226
Depression      3 17 24—26 48 50 52—53 143 148 227 320
Depression and dementia      253
Depression, bipolar      10 13 15 278—279

1 2 3 4 5 6 7 8

О проекте